Wall Street analysts are overwhelmingly bullish on Argenx SE (ARGX), with 10 analysts predicting the stock will reach at least $1,200 within 12 months from its current price of $919, representing potential upside of roughly 29%. The optimism is driven by strong sales growth from its Vyvgart franchise and a promising pipeline of autoimmune disease treatments. However, the company faces risks from ongoing clinical trials and declining sales in China.
Axe note: Wall Street analysts see substantial upside in Argenx’s stock, driven by solid biotech growth, yet key risks remain.